A Phase 1 interventional study of 100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) and Placebo in Hyperlipidemia, sponsored by Novartis Pharmaceuticals. Completed at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-25.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing inclisiran in Hyperlipidemias — 5 open to participants now, 8 under way, 5 of them phase 3. inclisiran · Hyperlipidemias.
Among the 11 studies testing inclisiran in Hyperlipidemias, this one is the 9th largest by enrollment, is one of 4 that started in 2021, is the only one in phase 1, and was the 1st registered.
862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.
Browse Hyperlipidemias studies →5 of the 11 studies testing inclisiran in Hyperlipidemias are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Argentina, Australia, Canada and 11 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Austria, China and 8 more countries
Ages 2–11
Novartis Pharmaceuticals · Sites in United States, Argentina, Austria and 20 more countries
Ages 6–11
Novartis Pharmaceuticals
Ages 18–100
First Affiliated Hospital of Xinjiang Medical University
Ages 18–75
By country, each count listing its studies:
inclisiran: first FDA approval 2021 (LEQVIO), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 4 started in 2021.
This study's enrollment of 40 is below the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Median enrollment 300 across the 11 interventional studies. Of the 3 that completed or were terminated, 2 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 3 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
13 studies in Hyperlipidemias by Novartis: 4 open now, 7 under way, 5 of them phase 3. Of 6 finished, 3 (50%) have results posted.
Among the 13 studies in Hyperlipidemias by Novartis, this one is the 11th largest by enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2021, is one of 2 in phase 1, and was the 3rd registered.
Novartis’s Hyperlipidemias studies by the year they started, since 2011.
3 of the studies testing inclisiran in Hyperlipidemias that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07102628Phase 3Novartis PharmaceuticalsEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | 2027-02-11 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT06249165Duke UniversityVictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 11 studies testing inclisiran in Hyperlipidemias, from their registry updates:
Among Novartis’s 13 in Hyperlipidemias:
This tab as a report to print or save as PDF → With an account.
Study to evaluate the pharmacokinetics and pharmacodynamics of inclisiran treatment given as single subcutaneous injection in Chinese participants with elevated low-density lipoprotein cholesterol (LDL-C) despite treatment with LDL-C lowering therapies
The purpose of the study is to characterize pharmacokinetics, pharmacodynamics, safety and tolerability of inclisiran in Chinese participants with elevated serum LDL-C to support inclisiran registration in China.Inclisiran is a long acting RNA therapeutic agent that inhibits the synthesis of PCSK9, leading to reduced circulating LDL-C levels. Three pivotal Phase III studies have been conducted primarily in non-Asian participants to support New Drug Application/Marketing Authorization Application approval of inclisiran globally. This study design is based on the hypothesis that the global inclisiran clinical data primarily obtained in Caucasian participants could be appropriately extrapolated to Chinese participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
300 mg inclisiran sodium (equivalent to 284 mg inclisiran) x 1 dose (n=15) at Day 1
Drug: 300 mg inclisiran sodium (equivalent to 284 mg inclisiran)
100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) x 1 dose (n=15) at Day 1
Drug: 100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)
Placebo x 1 dose (n=10) at Day 1
Drug: Placebo
100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) in 0.5 mL solution. Subcutaneous administration at Day 1
Also known as: KJX839
Inclisiran sodium 0mg (equivalent to inclisiran 0 mg) in 1.5 mL solution. Subcutaneous administration at Day 1
300 mg inclisiran sodium (equivalent to 284 mg inclisiran) in 1.5 mL solution. Subcutaneous administration at Day 1
Also known as: KJX839
PK parameters (Cmax) maximum peak observed plasma inclisiran concentration in treated participants
Pharmacokinetics parameters of inclisiran
Time frame: 0-48 hours post-dose
PK parameters (Tmax) time to reach maximum peak plasma inclisiran concentration in treated participants
Pharmacokinetics parameters of inclisiran
Time frame: 0-48 hours post-dose
PK parameters (T1/2) the elimination half-life associated with the terminal slope of a semi-logarithmic concentration-time curve in inclisiran treated participants
Pharmacokinetics parameters of inclisiran
Time frame: 0-48 hours post-dose
PK parameters (AUC) area under the plasma concentration-time curve in inclisiran treated participants
Pharmacokinetics parameters of inclisiran
Time frame: 0-48 hours post-dose
Percentage change in Proprotein convertase subtilisin kexin 9 (PCSK9) from baseline overtime
Pharmacodynamics effects of inclisiran
Time frame: Baseline to Days 5, 8, 15, 30, 60 and 90
Percentage change in Low density lipoprotein cholesterol (LDL-C) from baseline overtime
Pharmacodynamics effects of inclisiran
Time frame: Baseline to Days 5, 8, 15, 30, 60 and 90
Percent change from baseline to Days 30, 60 and 90 in PD parameter Proprotein convertase subtilisin kexin 9 (PCSK9)
Pharmacodynamics differences between inclisiran and placebo
Time frame: Baseline to Days 30, 60 and 90
Percent change from baseline to Days 30, 60 and 90 in PD parameter Low density lipoprotein cholesterol (LDL-C)
Pharmacodynamics differences between inclisiran and placebo
Time frame: Baseline to Days 30, 60 and 90
Rate of formation of anti-drug antibodies to Inclisiran
Immunogenicity of inclisiran
Time frame: Baseline, Days 30 and 90
Plan to share: No
Ran from Feb 2021 to primary completion in Oct 2021, 7 months.
Of 47 industry-sponsored phase 1 interventional studies under Hyperlipidemias, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 10. This study's 7 months is above that.
Counting every sponsor, half of 54 studies reached it within 3 months; a quarter within 1 and three quarters within 10.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inclisiran